In addition to serving as President and C.E.O. of Tepha, Dr. Williams also serves on the board of directors.

Dick Emmitt, a director of Tepha, is a general partner of The Vertical Group, a New Jersey based medical device venture firm that succeeded the venture capital activities of F. Eberstadt & Co.  With more than thirty years experience in related venture capital, investment banking, and equity research activities, Mr. Emmitt is recognized as one of the leading experts on the health care industry.  He currently serves on the board of several public medical device companies, including American Medical Systems and Wright Medical Group.  Mr. Emmitt has also been involved in the successful development of SciMed Life Systems and Xomed Surgical Products, which were ultimately acquired by Boston Scientific and Medtronic.  He holds an M.B.A. from Rutgers School of Business.

Edward Giles, a director of Tepha, has been the chairman of The Vertical Group since 1988.  From 1979 through 1985, he was president of F. Eberstadt & Co., and then vice chairman of Eberstadt Fleming.  Mr. Giles received a B.Ch.E. from Princeton University and a S.M. in industrial management from the Massachusetts Institute of Technology.

Edward Muller, a director of Tepha, is chairman of Metabolix, where from 1993 to 1999, he also served as president.  Prior to joining Metabolix, Mr. Muller served Halcon International in a number of functions, both technical and financial, ultimately assuming C.E.O. responsibilities.  Halcon was responsible for the development of several key processes used in the production of raw materials for the polyester, nylon, polystyrene, and polyurethane industries.  Mr. Muller was active in technology evaluation, financing and planning, and structuring of ventures to utilize these technologies.  He received a B.Ch.E. from The Cooper Union and an M.B.A. from New York University.

Dr. Sinskey, a director of Tepha and a cofounder of Metabolix, is a professor in the Department of Biology at the Massachusetts Institute of Technology.  He is also co-director of M.I.T.'s Program on the Pharmaceutical Industry (POPI).  A joint inventor (with Dr. Oliver Peoples) of Tepha's key patents, Dr. Sinskey is a well-recognized expert on strategies and techniques for producing the Company’s biomaterials.  He is also a cofounder and director of Merrimack Pharmaceuticals, a leading biopharmaceutical company in the emerging area of network biology; plus he was a member of the founding technical and scientific advisory team at Genzyme.  Dr. Sinskey earned a Sc.D. from M.I.T.